Allogenic hematopoietic cell transplant a viable option for high-risk myelodysplastic syndrome, study suggests

Evidence suggests that allogenic hematopoietic cell transplantation (HCT) improves overall survival in patients with myelodysplastic syndrome (MDS), a serious blood disorder, when compared with best available supportive care. But MDS is a heterogeneous disease and questions remained about how cancer-related genetic mutations influence outcomes.